
Wellesley Pharmaceuticals, based in Newtown, US, develops Paxerol, a solution for Nocturia.
Wellesley Pharmaceuticals, founded in Newtown, US, is dedicated to addressing the medical condition of nocturia, which affects approximately 2.4 billion people worldwide. Their core mission is to improve the quality of life for individuals suffering from frequent nighttime urination. The company’s flagship product, Paxerol, is specifically designed to provide a solution for nocturia, aiming to reduce the number of nightly bathroom visits and enhance sleep quality.
Key figures associated with Wellesley Pharmaceuticals include its founders and notable investors who have supported the development of Paxerol. The company has achieved significant milestones in the pharmaceutical industry by bringing attention to nocturia and offering an effective treatment option. The impact of their work is reflected in the improved sleep and overall well-being of their users, positioning Wellesley Pharmaceuticals as a pivotal player in the healthcare sector focused on urinary health.

Woolsey Pharmaceuticals
woolseypharma.com

Somnus Therapeutics
somnusthera.com

PleoPharma
pleopharma.com

Wilmington Pharmaceuticals

PellePharm
pellepharm.com

Welmedix Consumer Healthcare
welmedix.com

Welwaze Medical
welwaze.com

Fervent Pharmaceuticals
ferventpharma.com

Concours Pharmaceuticals
White Sands Pharma

Manhattan Pharmaceuticals

Petros Pharmaceuticals
petrospharma.com

Aquestive Therapeutics
aquestive.com
Assertio Holdings

Valcrest Pharmaceuticals
Companies similar to Wellesley Pharmaceuticals include Woolsey Pharmaceuticals, Somnus Therapeutics, PleoPharma and Wilmington Pharmaceuticals.
Wellesley Pharmaceuticals was founded in 2011.
Wellesley Pharmaceuticals' headquarters is located in Newtown, PA, US.
Wellesley Pharmaceuticals' most recent funding round was for $7M (USD) in January 2016.
As of Jan 1, 2016, Wellesley Pharmaceuticals has raised a total of $7.9M (USD).
Wellesley Pharmaceuticals has 30 employees as of Feb 5, 2024.